Cargando…

The AKT/GSK3β-Mediated Slug Expression Contributes to Oxaliplatin Resistance in Colorectal Cancer via Upregulation of ERCC1

Although oxaliplatin serves as one of the first-line drugs prescribed for treating colorectal cancer (CRC), the therapeutic effect is disappointing due to drug resistance. So far, the molecular mechanisms mediating oxaliplatin resistance remain unclear. In this study, we found the chemoresistance in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Wei, Ma, Xiao-Dong, Jiang, Guan-Min, Shi, Bin, Zhong, Wen, Sun, Chun-Lei, Zhao, Liang, Hou, Yan-Jiao, Wang, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cognizant Communication Corporation 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851510/ https://www.ncbi.nlm.nih.gov/pubmed/32331534 http://dx.doi.org/10.3727/096504020X15877284857868

Ejemplares similares

Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer
por: Baba, H, et al.
Publicado: (2012)

KIF11 is upregulated in colorectal cancer and silencing of it impairs tumor growth and sensitizes colorectal cancer cells to oxaliplatin via p53/GSK3β signaling
por: Zhou, Yan, et al.
Publicado: (2021)

GTW inhibits the Epithelial to Mesenchymal Transition of Epithelial Ovarian Cancer via ILK/AKT/GSK3β/Slug Signalling Pathway
por: Feng, Ying, et al.
Publicado: (2021)

SHED-derived exosomes ameliorate hyposalivation caused by Sjögren's syndrome via Akt/GSK-3β/Slug-mediated ZO-1 expression
por: Du, Zhihao, et al.
Publicado: (2023)

IGHG1 upregulation promoted gastric cancer malignancy via AKT/GSK-3β/β-Catenin pathway
por: Li, Xinyu, et al.
Publicado: (2021)

Association of ERCC1 and ERCC2 polymorphisms with colorectal cancer risk in a Chinese population
por: Ni, Min, et al.
Publicado: (2014)

Expression analysis of E-cadherin, Slug and GSK3β in invasive ductal carcinoma of breast
por: Prasad, Chandra P, et al.
Publicado: (2009)

Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy
por: Chen, Jianfang, et al.
Publicado: (2016)

XPF–ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer
por: Huang, Ming-Yii, et al.
Publicado: (2023)

Upregulated IQUB promotes cell proliferation and migration via activating Akt/GSK3β/β‐catenin signaling pathway in breast cancer
por: Li, Kai, et al.
Publicado: (2018)

Emodin Inhibits the Epithelial to Mesenchymal Transition of Epithelial Ovarian Cancer Cells via ILK/GSK-3β/Slug Signaling Pathway
por: Lu, Jingjing, et al.
Publicado: (2016)

Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil
por: Han, Jae Joon, et al.
Publicado: (2014)

ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
por: Baek, Moo-Jun
Publicado: (2015)

AKT/GSK3β Signaling in Glioblastoma
por: Majewska, Ewelina, et al.
Publicado: (2016)

Eurycomanone stimulates bone mineralization in zebrafish larvae and promotes osteogenic differentiation of mesenchymal stem cells by upregulating AKT/GSK-3β/β-catenin signaling
por: Zhong, Yan-ting, et al.
Publicado: (2023)

PIK3CD induces cell growth and invasion by activating AKT/GSK‐3β/β‐catenin signaling in colorectal cancer
por: Chen, Jing‐Song, et al.
Publicado: (2019)

Shikonin Attenuates Acetaminophen-Induced Hepatotoxicity by Upregulation of Nrf2 through Akt/GSK3β Signaling
por: Li, Huachao, et al.
Publicado: (2018)

Upregulation of lnc-ZNF281 Inhibits the Progression of Glioma via the AKT/GSK-3β/β-Catenin Signaling Pathway
por: Deng, Yu-Qin, et al.
Publicado: (2021)

Curcumin Regulates ERCC1 Expression and Enhances Oxaliplatin Sensitivity in Resistant Colorectal Cancer Cells through Its Effects on miR-409-3p
por: Han, Wei, et al.
Publicado: (2020)

ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas
por: Orlandi, A., et al.
Publicado: (2015)

Analysis of ERCC1 and ERCC2 gene variants in osteosarcoma, colorectal and breast cancer
por: GÓMEZ-DÍAZ, BENJAMÍN, et al.
Publicado: (2015)

Upregulation of SLUG expression in canine mammary gland tumors and its prognostic significance
por: Cheon, Soo-Bin, et al.
Publicado: (2023)

Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling
por: Wang, Cun, et al.
Publicado: (2016)

Transforming growth factor-β1 contributes to oxaliplatin resistance in colorectal cancer via epithelial to mesenchymal transition
por: Mao, Liang, et al.
Publicado: (2017)

Suppressed Akt/GSK-3β/β-catenin signaling contributes to excessive adipogenesis of fibro-adipogenic progenitors after rotator cuff tears
por: Lin, Xingzuan, et al.
Publicado: (2023)

Epistatic SNP interaction of ERCC6 with ERCC8 and their joint protein expression contribute to gastric cancer/atrophic gastritis risk
por: Jing, Jing-Jing, et al.
Publicado: (2017)

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
por: Basso, M, et al.
Publicado: (2013)

Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin
por: Rao, Devika, et al.
Publicado: (2019)

CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer
por: Hsieh, Chi-Che, et al.
Publicado: (2022)

NUAK1 promotes tumor metastasis through upregulating slug transcription in esophageal squamous cell carcinoma
por: Yang, Huiru, et al.
Publicado: (2023)

Twist2 contributes to cisplatin-resistance of ovarian cancer through the AKT/GSK-3β signaling pathway
por: WANG, TIAN, et al.
Publicado: (2014)

Upregulated UCA1 contributes to oxaliplatin resistance of hepatocellular carcinoma through inhibition of miR‐138‐5p and activation of AKT/mTOR signaling pathway
por: Huang, Guolin, et al.
Publicado: (2021)

GSK-3β suppresses HCC cell dissociation in vitro by upregulating epithelial junction proteins and inhibiting Wnt/β-catenin signaling pathway
por: Zhang, Jing-Hua, et al.
Publicado: (2017)

SLUG Manual - SLUG Interface to GEANT
por: DeWolf, R S
Publicado: (1993)

Renoprotective Effects of Atorvastatin in Diabetic Mice: Downregulation of RhoA and Upregulation of Akt/GSK3
por: Bruder-Nascimento, Thiago, et al.
Publicado: (2016)

IRS-2/Akt/GSK-3β/Nrf2 Pathway Contributes to the Protective Effects of Chikusetsu Saponin IVa against Lipotoxicity
por: Wang, Lei, et al.
Publicado: (2021)

Relationship between the Asp1104His polymorphism of the nucleotide excision repair gene ERCC5 and treatment sensitivity to oxaliplatin in patients with advanced colorectal cancer in China
por: Kong, Jiangying, et al.
Publicado: (2018)

Girdin acts as an oncogene in gastric cancer by regulating AKT/GSK3β/β-catenin signaling
por: Wang, Yun, et al.
Publicado: (2023)

ERCC1 and ERCC2 Variants Predict Survival in Gastric Cancer Patients
por: Li, Yangkai, et al.
Publicado: (2013)

PCDH8 inhibits glioma cell proliferation by negatively regulating the AKT/GSK3β/β-catenin signaling pathway
por: Zong, Zhenkun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_d8ecf4i22sscd5utc98vgka02l